These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 34329687)
21. In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. Sakagami M Adv Drug Deliv Rev; 2020; 161-162():63-74. PubMed ID: 32763274 [TBL] [Abstract][Full Text] [Related]
22. An overview of regulations for bioequivalence assessment of locally acting orally inhaled drug products for the United States, Europe, Canada, and India. Patil PP; Pawar AP; Mahadik KR; Gaikwad VL Expert Opin Drug Deliv; 2021 Dec; 18(12):1843-1855. PubMed ID: 34814778 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic Bioequivalence between Generic and Originator Orally Inhaled Drug Products: Validity of Administration of Doses above the Approved Single Maximum Dose. Singh GJP; Hickey AJ Mol Pharm; 2024 Sep; 21(9):4191-4198. PubMed ID: 39133824 [TBL] [Abstract][Full Text] [Related]
24. An updated overview with simple and practical approach for developing in vitro-in vivo correlation. Jacob S; Nair AB Drug Dev Res; 2018 May; 79(3):97-110. PubMed ID: 29697151 [TBL] [Abstract][Full Text] [Related]
25. In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches. Forbes B; Bäckman P; Christopher D; Dolovich M; Li BV; Morgan B AAPS J; 2015 Jul; 17(4):837-52. PubMed ID: 25940082 [TBL] [Abstract][Full Text] [Related]
26. Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling. Zhang J; Wu K; Liu B; Hou S; Li X; Ye X; Liu J; He Q Front Med (Lausanne); 2023; 10():1056318. PubMed ID: 36824609 [TBL] [Abstract][Full Text] [Related]
27. The importance of dissolution for orally inhaled drug products: pharmaceutical, regulatory, and clinical considerations. Somby K; Hingle M; Tomic I; Forbes B Expert Opin Drug Deliv; 2023; 20(8):1033-1036. PubMed ID: 37078605 [No Abstract] [Full Text] [Related]
28. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report. Evans C; Cipolla D; Chesworth T; Agurell E; Ahrens R; Conner D; Dissanayake S; Dolovich M; Doub W; Fuglsang A; García Arieta A; Golden M; Hermann R; Hochhaus G; Holmes S; Lafferty P; Lyapustina S; Nair P; O'Connor D; Parkins D; Peterson I; Reisner C; Sandell D; Singh GJ; Weda M; Watson P J Aerosol Med Pulm Drug Deliv; 2012 Jun; 25(3):117-39. PubMed ID: 22413806 [TBL] [Abstract][Full Text] [Related]
29. Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data. Chen S; Morgan B; Beresford H; Burmeister Getz E; Christopher D; Långström G; Strickland H; Wiggenhorn C; Lyapustina S AAPS PharmSciTech; 2019 Aug; 20(7):296. PubMed ID: 31444601 [TBL] [Abstract][Full Text] [Related]
30. Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. Lewis DA; Young PM; Buttini F; Church T; Colombo P; Forbes B; Haghi M; Johnson R; O'Shea H; Salama R; Traini D Eur J Pharm Biopharm; 2014 Jan; 86(1):31-7. PubMed ID: 23523547 [TBL] [Abstract][Full Text] [Related]
31. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence. Christopher D; Adams W; Amann A; Bertha C; Byron PR; Doub W; Dunbar C; Hauck W; Lyapustina S; Mitchell J; Morgan B; Nichols S; Pan Z; Singh GJ; Tougas T; Tsong Y; Wolff R; Wyka B AAPS PharmSciTech; 2007 Nov; 8(4):E90. PubMed ID: 18181550 [TBL] [Abstract][Full Text] [Related]
32. Conjunction of semi-mechanistic in vitro-in vivo modeling and population pharmacokinetics as a tool for virtual bioequivalence analysis - a case study for a BCS class II drug. Danielak D; Paszkowska J; Staniszewska M; Garbacz G; Terlecka A; Kubiak B; Romański M Eur J Pharm Biopharm; 2023 May; 186():132-143. PubMed ID: 37015321 [TBL] [Abstract][Full Text] [Related]
33. In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation. Newman SP; Chan HK Adv Drug Deliv Rev; 2020 Dec; 167():135-147. PubMed ID: 32593641 [TBL] [Abstract][Full Text] [Related]
34. Inhaled formulation and device selection: bridging the gap between preclinical species and first-in-human studies. Wylie JL; House A; Mauser PJ; Sellers S; Terebetski J; Wang Z; Ehrick JD Ther Deliv; 2018 May; 9(5):387-404. PubMed ID: 29681239 [TBL] [Abstract][Full Text] [Related]
35. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe. Limberg J; Potthast H Biopharm Drug Dispos; 2013 Jul; 34(5):247-53. PubMed ID: 23585295 [TBL] [Abstract][Full Text] [Related]
36. In vitro - In vivo correlation in the development of oral drug formulation: A screenshot of the last two decades. Davanço MG; Campos DR; Carvalho PO Int J Pharm; 2020 Apr; 580():119210. PubMed ID: 32173499 [TBL] [Abstract][Full Text] [Related]
37. From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers. Karalis V; Magklara E; Shah VP; Macheras P Pharm Res; 2010 Sep; 27(9):2018-29. PubMed ID: 20635193 [TBL] [Abstract][Full Text] [Related]
39. Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study. Wang J; Chen J; Wang L; Yang D; Shao R; Lou H; Ruan Z; Jiang B Clin Transl Sci; 2023 Jan; 16(1):85-91. PubMed ID: 36178248 [TBL] [Abstract][Full Text] [Related]
40. Modeling and simulation of biopharmaceutical performance. Zhang X; Lionberger RA Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]